that LipiGesic M has been shown to be highly effective and works as well as the number-one-selling prescription migraine treatment without the severe side effects often caused by chemical compounds. Since it is an OTC product, LipiGesic M is available without a doctor's prescription at far less cost. This availability will be increasingly important as insurance premiums, co-pays and deductibles continue to rise in response to changes prompted by the Affordable Care Act."
Thus, if PMBS gains 1% of the migraine market that would result in approximately 400,000 consumers buying LipiGesic M at a retail price of $19.95; that equates to nearly $8 million in sales.
In addition, consumers with acute migraines that recur two to three times a month who find LipiGesic M an effective migraine relief product would be expected to buy nine (9) boxes per year creating a potential of $72 million in annual sales.
These numbers are calculated based on just 1% of the migraine market.
To view the full report, and access risks, disclosures, and potential outlook visit http://www.wallstreetnewscast.com/profile/pmbs.html
About PuraMed BioScience, Inc.
PuraMed BioScience engages in the research, development, and marketing of non-prescription medicinal and healthcare products. In addition to LipiGesic® M, PuraMed BioScience plans to launch LipiGesic® H for tension-type headaches and LipiGesic® PM, which provides a remedy for insomnia and other sleep disorders. www.puramedbioscience.com
This news release contains forward-looking statements regarding PuraMed BioScience, Inc., and its future business plans, which statements involve known and unknown risks and uncertainties that may cause actual results and future achievements of PuraMed BioScience to be mater
Page: 1 2 3 Related biology technology :1
|SOURCE PuraMed BioScience, Inc.|
Copyright©2012 PR Newswire.
All rights reserved
. PuraMed BioScience, Inc. Appoints Sue A. Baacke, CPA, as CFO2
. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors3
. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer4
. Kansas Bioscience Authority Announces FY11 Outcomes of $207 Million5
. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.6
. Coronado Biosciences to Present at the Oppenheimer 22nd Annual Healthcare Conference7
. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology8
. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting9
. Ohios Bioscience Industry Effort Paying Off With Increase in Graduates and Accolades for the State10
. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference11
. Roka Bioscience Secures $47.5 Million in Series D Financing